<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="782">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150977</url>
  </required_header>
  <id_info>
    <org_study_id>2021-03458</org_study_id>
    <nct_id>NCT05150977</nct_id>
  </id_info>
  <brief_title>Idiopathic Hypersomnia</brief_title>
  <acronym>IDAHO</acronym>
  <official_title>Idiopathic Hypersomnia - a Retrospective Characterization Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic hypersomnia (IH) is characterized by non-restoring night-time sleep, excessive&#xD;
      daytime sleepiness, sleep inertia, impaired cognitive functioning and autonomic symptoms. IH&#xD;
      seems to be long lasting, once established, but little is known about long-time consequences,&#xD;
      and research on the relationship between idiopathic hypersomnia and all-cause mortality is&#xD;
      however sparse. IH is thus a poorly characterized disorder of hypersomnolence, and the&#xD;
      present study aims to answer the following research questions:&#xD;
&#xD;
        1. Are there subgroups within the IH-group, that can be retrospectively characterized out&#xD;
           of data from polysomnography, PSG and MSLT.&#xD;
&#xD;
        2. What are the relationships between IH, and possible IH subgroups, and morbidity,&#xD;
           mortality, and sick leave, using retrospective register data?&#xD;
&#xD;
        3. What is the natural course of IH, and possible IH subgroups, assessed with&#xD;
           questionnaires that measures daytime sleepiness, depression, and insomnia?&#xD;
&#xD;
        4. How do subjects diagnosed with IH think about their disease, cope with it, and perceive&#xD;
           the effects of treatments, using qualitative interviews? 185 individuals assessed and&#xD;
           diagnosed at the Sleep unit, Uppsala university hospital between 2010-01-01 and&#xD;
           2019-12-31 will be contacted. After collecting informed consents, PSG and MSLT data will&#xD;
           be analysed together with register data regarding morbidity, mortality, sick leave, and&#xD;
           pharmacotherapy.Questionnaires used at the time of the original assessment will be&#xD;
           reviewed and, to study the natural course of the syndrome, the same questionnaires will&#xD;
           be sent to the participants by mail.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography</measure>
    <time_frame>Baseline</time_frame>
    <description>Spectral analyses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple sleep latency test</measure>
    <time_frame>Baseline</time_frame>
    <description>Sleep latency and REM latency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>1 week</time_frame>
    <description>Diagnoses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sick leave</measure>
    <time_frame>1 week</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacotherapy</measure>
    <time_frame>1 week</time_frame>
    <description>Type and dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Problem Acceptance Questionnaire</measure>
    <time_frame>1 week</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Ã…sberg Depression Rating Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal Type Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Munich Parasomnia Screening</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ullanlinna Narcolepsy Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Score on a scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hypersomnia, Idiopathic</condition>
  <arm_group>
    <arm_group_label>Idiopathic hypersomnia</arm_group_label>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Polysomnography</intervention_name>
    <description>Reviewing collected data</description>
    <arm_group_label>Idiopathic hypersomnia</arm_group_label>
    <other_name>Multiple sleep latency test</other_name>
    <other_name>Questionnaires</other_name>
    <other_name>Register data</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects are 185 individuals with idiopathic hypersomnia (IH) assessed and&#xD;
        diagnosed using polysomnography and multiple sleep latency test at the Sleep unit, Uppsala&#xD;
        university hospital between 2010-01-01 and 2019-12-31. Inclusion criteria is IH, according&#xD;
        to the ICSD-3.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic hypersomnia, according to the The International Classification of Sleep&#xD;
             Disorders - Third Edition (ICSD-3)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other serious somatic or psychiatric disease&#xD;
&#xD;
          -  Drug additction with drug seeking behaviour&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Karlsten, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Idiopathic Hypersomnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

